Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data CG Oncology, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Revenue
0.2
1.14
4.04
Research and development
45.8
82.1
117
General and administrative
9.9
33.7
73.5
Operating expenses
55.7
116
Operating income
-55.4
-115
-191
Interest income
6.9
26.6
29.9
Other non-operating income
6.84
26.6
29.8
Income tax
0
0
-0.27
Net income
-48.6
-88
-161
EBITDA
-55.4
-115
-189
EPS, basic
-15.65
-1.41
-2.08
EPS, diluted
-15.65
-1.41
-2.08
Shares, basic (weighted)
4.33
62.5
77.3
Shares, diluted (weighted)
4.33
62.5
77.3
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
8.27
257
32.5
Short-term investments
179
485
710
Receivables
0
0.69
Inventory
0
1.57
Other current assets
6.36
12.2
15.1
Total current assets
194
754
759
Property, plant and equipment
0.07
0.27
15.6
Lease right-of-use assets
0.42
0.22
3.97
Goodwill
0
10.3
Intangible assets
0
0.58
Other non-current assets
0.02
0.09
1.68
Total assets
199
755
792
Accounts payable
3.24
6.52
5.71
Total current liabilities
14.3
21.4
30.8
Long-term debt
0
3
Lease liabilities
0.24
0.05
3.11
Other non-current liabilities
0
1.74
Total liabilities
14.5
21.4
39
Total debt
0
3
Paid-in capital
6.84
951
1,132
Retained earnings
-130
-218
-379
Shareholders' equity
-123
733
753
Total equity
-123
733
753
Total liabilities and equity
199
755
792
Shares outstanding
5.22
76.2
80.7
Cash flow statement
FY2024
FY2024
FY2025
Net income
-48.6
-88
-161
Depreciation and amortization
0.02
0.03
1.45
Stock-based compensation
1.53
11.4
26.7
Deferred income tax
-0.28
Change in receivables
-0.32
Change in inventory
-0.44
Change in payables
2.01
3.28
-1.64
Cash from operations
-45.7
-78.7
-132
Capital expenditures
-0.23
-0.13
Acquisitions
-22
Purchases of investments
-518
-1,046
-1,068
Sales and maturities of investments
396
745
844
Cash from investing
-121
-301
-246
Stock issued
2.08
223
147
Cash from financing
87
628
154
Net change in cash
-79.9
249
-225
Free cash flow
-78.9
-132
Interest paid
0.38
0.1
Income taxes paid
0.02
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $67.15 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-4,056.0%
Operating income / revenue.
EBITDA margin
-4,007.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-3,603.0%
Net income / revenue.
FCF margin
-2,880.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-2,866.0%
Cash from operations / revenue.
Return on equity (ROE)
-21.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-20.7%
Net income / average total assets.
Return on invested capital (ROIC)
-19.7%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
2,508.0%
Research and development expense / revenue.
Stock-based pay / revenue
567.2%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
14.1%
Capital expenditures / revenue.
D&A / revenue
48.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
254.7%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
2.6%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
4.9%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
23.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
22.2x
Current assets / current liabilities.
Quick ratio
21.8x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
21.8x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.00x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
0.3%
Total debt / total assets.
Liabilities / assets
5.2%
Total liabilities / total assets.
Net debt
-$1.03B
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.07
Revenue / diluted weighted shares.
FCF per share
-$2.03
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.02
Cash from operations / diluted weighted shares.
Book value per share
$11.65
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
956x
Market cap / revenue.
P/B
5.78x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
5.85x
Market cap / tangible book value, when positive.
EV/Sales
791x
Enterprise value / revenue.
FCF yield
-3.0%
Free cash flow / market cap.
Earnings yield
-3.8%
Net income / market cap (the inverse of P/E).
What was CG Oncology, Inc.'s revenue in fiscal 2025?
CG Oncology, Inc. reported revenue of $4.0M for fiscal 2025, 254.7% higher than the year before.
Was CG Oncology, Inc. profitable in fiscal 2025?
No. It reported a net loss of $161.0M.
How much free cash flow did CG Oncology, Inc. generate in fiscal 2025?
Cash from operations of $132.3M minus capital expenditures of $134.0K left free cash flow of -$132.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.